Cargando…

Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients

Detalles Bibliográficos
Autores principales:	Valdez, H, Chapman, D, Biswai, P, Lewis, M, Craig, C, Heera, J, Ellery, S, Swenson, LC, Harrigan, PR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112823/ http://dx.doi.org/10.1186/1758-2652-13-S4-O11

Ejemplares similares

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

Calibration and accuracy of the geno2pheno co-receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotype
por: Swenson, LC, et al.
Publicado: (2010)

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
por: Lazzarin, A, et al.
Publicado: (2010)

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
por: Garcia, Federico, et al.
Publicado: (2014)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
por: Jubb, Becky, et al.
Publicado: (2019)

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies
por: Jacqmin, P, et al.
Publicado: (2013)

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial
por: van Lelyveld, Steven F. L., et al.
Publicado: (2015)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014)

Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients
por: Cohen, C, et al.
Publicado: (2010)

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
por: Portsmouth, S, et al.
Publicado: (2010)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4(+) Cell Rises in HIV-Infected Patients
por: Funderburg, Nicholas, et al.
Publicado: (2010)

The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks
por: VanderVeen, Laurie, et al.
Publicado: (2021)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017)

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens
por: Lewis, ME, et al.
Publicado: (2021)

Factors Predicting the Efficacy of Adefovir Dipivoxil on Treatment-Naïve Chronic Hepatitis B Patients at 48 Weeks
por: Wang, Li-Chun, et al.
Publicado: (2011)

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)
por: Rockstroh, J, et al.
Publicado: (2010)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
por: Raffi, François, et al.
Publicado: (2015)

Bone Deleterious Effects of Different NRTIs in Treatment-naïve HIV Patients After 12 and 48 Weeks of Treatment
por: Atencio, Patricia, et al.
Publicado: (2021)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Increased percentages of calprotectin and TNF-Α double-positive monocytes in the acute phase of Kawasaki disease
por: Cimaz, Rolando, et al.
Publicado: (2011)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B
por: Kim, In Hee, et al.
Publicado: (2010)

Baracle(®) vs Baraclude(®) for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety
por: Kim, Do Young, et al.
Publicado: (2017)

Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc
por: Borm, Katharina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u55r04nulvhflfj7v2mpp7peob